Imatinib Krka D.D. (Imatinib)

Imatinib blocks the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing phosphorylation of these enzymes, it stops downstream signalling that promotes cell proliferation and survival, leading to apoptosis of the malignant cells that depend on these pathways.

The exact dose of Imatinib Krka D.D. is determined by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other individual factors. Patients should follow the dose and schedule written on their prescription without alteration.

Safety data for Imatinib in pregnancy and lactation are limited. Animal studies suggest potential fetal risk, and the drug is excreted in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for many patients. Newer agents such as dasatinib or nilotinib may offer faster molecular responses or activity against certain resistant mutations, but they can have different side‑effect profiles and drug‑interaction potentials. Choice of therapy depends on disease characteristics, patient tolerance and physician judgment.

Imatinib tablets should be stored at ambient temperature, below 25 °C, in the original blister or bottle, protected from moisture and direct light. Keep the container tightly closed and out of reach of children. Do not store in the refrigerator or freezer.

Imatinib is taken orally, usually once daily, with a glass of water. It can be taken with or without food, but a consistent routine helps maintain stable blood levels. Patients should swallow the tablet whole and avoid crushing or chewing unless instructed otherwise.

Serious adverse events include hepatotoxicity, severe neutropenia or thrombocytopenia, cardiac failure, pulmonary hypertension, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts, cardiac function and any new skin or respiratory symptoms.

Imatinib is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or pre‑existing severe cytopenias. The medication should only be used under the supervision of a qualified healthcare professional.